AU2012327231B2 — Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) and polyethylene oxide
Assigned to Purdue Pharma LP · Expires 2015-09-24 · 11y expired
What this patent protects
- 131 The present invention relates to a solid extended release pharmaceutical dosage form, comprising a mixture in the form of an extended release matrix formulation, the mixture comprising at least: (1) at least one poly(z-caprolactone), and (2) at least one polyethylene oxide,…
USPTO Abstract
- 131 The present invention relates to a solid extended release pharmaceutical dosage form, comprising a mixture in the form of an extended release matrix formulation, the mixture comprising at least: (1) at least one poly(z-caprolactone), and (2) at least one polyethylene oxide, and (3) at least one active agent.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.